Cipla eyes rebound in ‘One India’ business despite slow seasonal growth 0 05.11.2024 13:10 Thehindubusinessline.com Despite facing supply issues with its generic Lanreotide in the US, Cipla anticipates a recovery in sales starting from Q4 FY25. Партнёры Smi24.net Все новости за 24 часа Музыкальные новости Агрегатор новостей 24СМИ
